98%
921
2 minutes
20
With refinements in electromagnetics, diverse medical applications have evolved to detect diseases efficaciously. Breast cancer, a dominant cause of mortality among women worldwide, necessitates early diagnosis and screening for timely medical intervention. This research establishes the design, simulation, and analysis of an advanced triangular slotted circular flexible Ultra-wideband (UWB) antenna optimized for breast cancer detection and healthcare monitoring. The proposed antenna employs an extensive frequency range of 2.95 GHz to 24.2 GHz, accomplishing an impressive impedance bandwidth of 156%. It authenticates directional and omnidirectional radiation patterns with compact dimensions of 46.3 × 52.6 × 1.076 mm³. Key aspects divulge a resonance frequency at 14.35 GHz with a significant input reflection coefficient of -37.8 dB. The antenna achieves a peak gain of 3.16 dB at 5.8 GHz, with efficiencies of 59.56% and 66.88% at 5.8 GHz and 4.48 GHz, respectively. A meticulous case study involving SAR evaluation confirms the antenna's safe exposure levels. For a flat human phantom, SAR values are 0.774 W/kg at 13.5 GHz and 0.712 W/kg at 14.35 GHz for 10 gm of tissue. For the breast phantom model, SAR values are 0.201 W/kg at 11.4 GHz and 0.152 W/kg at 14.35 GHz for 10 gm of tissue. Besides that, the antenna's flexible design promises an excellent execution under several bending conditions, making it ideal for wearable applications. These findings establish the antenna as an efficient solution for breast cancer detection and healthcare monitoring, combining safety, flexibility, and the aptness to ameliorate early diagnosis while lowering mortality rates. Wearable antennas are pivotal for advanced healthcare applications. This section presents the literature and discusses the work related to flexible UWB antenna designed for breast cancer detection and healthcare monitoring, tackling challenges in early diagnosis and patient care.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12005557 | PMC |
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0320806 | PLOS |
Int J Dermatol
September 2025
Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Introduction: Cutaneous scalp metastases from breast carcinoma (CMBC) represent an uncommon manifestation of metastatic disease, with heterogeneous clinical presentations, including nodular or infiltrative lesions and scarring alopecia (alopecia neoplastica). The absence of standardized diagnostic criteria, particularly for alopecic phenotypes, poses challenges to early recognition of CMBC, which may represent either the first indication of neoplastic progression or a late recurrence.
Materials And Methods: We retrospectively analyzed a multicenter cohort of 15 patients with histologically confirmed CMBC.
Research (Wash D C)
September 2025
State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype, characterized by a high propensity for metastasis, poor prognosis, and limited treatment options. Research has demonstrated a substantial correlation between the expression of protein arginine N-methyltransferase 1 (PRMT1) and enhanced proliferation, metastasis, and poor outcomes in TNBC. However, the specific role of PRMT1 in lung metastasis and chemoresistance remains unclear.
View Article and Find Full Text PDFBiochem Biophys Rep
December 2025
Division of Breast Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei, 112, Taiwan.
Purpose: This study aimed to conduct functional proteomics across breast cancer subtypes with bioinformatics analyses.
Methods: Candidate proteins were identified using nanoscale liquid chromatography with tandem mass spectrometry (NanoLC-MS/MS) from core needle biopsy samples of early stage (0-III) breast cancers, followed by external validation with public domain gene-expression datasets (TCGA TARGET GTEx and TCGA BRCA).
Results: Seventeen proteins demonstrated significantly differential expression and protein-protein interaction (PPI) found the strong networks including COL2A1, COL11A1, COL6A1, COL6A2, THBS1 and LUM.
RSC Med Chem
August 2025
Department of Chemistry and Biochemistry, Baylor University, One Bear Place #97348, Waco, TX 76798-7348, United States of America.
A strategy for targeting tumor-associated hypoxia utilizes reductase enzyme-mediated cleavage to convert biologically inert prodrugs to their corresponding biologically active parent therapeutic agents selectively in areas of pronounced hypoxia. Small-molecule inhibitors of tubulin polymerization represent unique therapeutic agents for this approach, with the most promising functioning as both antiproliferative agents (cytotoxins) and as vascular disrupting agents (VDAs). VDAs selectively and effectively disrupt tumor-associated microvessels, which are typically fragile and chaotic in nature.
View Article and Find Full Text PDFMater Today Bio
October 2025
School of Pharmacy, Henan Medical University, Xinxiang, Henan, China.
Breast cancer continues to present a major clinical hurdle, largely attributable to its aggressive metastatic behavior and the suboptimal efficacy of standard chemotherapeutic regimens. Cisplatin (CDDP) is a representative platinum drug in the treatment of breast cancer, however, its therapeutic application is often constrained by systemic toxicity and the frequent onset of chemoresistance. Here, we introduce a novel charge-adaptive nanoprodrug system, referred to as PP@, engineered to respond to tumor-specific conditions.
View Article and Find Full Text PDF